Insulet (NASDAQ:PODD – Get Rating) and Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Earnings and Valuation
This table compares Insulet and Intelligent Bio Solutions' gross revenue, earnings per share and valuation.
Get Insulet alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insulet | $1.10 billion | 18.05 | $16.80 million | $0.24 | 1,189.58 |
| Intelligent Bio Solutions | $440,000.00 | 34.16 | -$8.31 million | ($0.56) | -1.46 |
Insulet has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Insulet has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.Analyst Recommendations
This is a summary of recent ratings and recommmendations for Insulet and Intelligent Bio Solutions, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insulet | 0 | 5 | 9 | 0 | 2.64 |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
Insulet currently has a consensus target price of $309.23, suggesting a potential upside of 8.31%. Given Insulet's higher possible upside, equities research analysts plainly believe Insulet is more favorable than Intelligent Bio Solutions.
Institutional & Insider Ownership
2.3% of Intelligent Bio Solutions shares are owned by institutional investors. 0.9% of Insulet shares are owned by insiders. Comparatively, 1.9% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Insulet and Intelligent Bio Solutions' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insulet | 1.35% | 18.19% | 4.02% |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
Summary
Insulet beats Intelligent Bio Solutions on 9 of the 13 factors compared between the two stocks.
About Insulet
(Get Rating)
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
About Intelligent Bio Solutions
(Get Rating)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.